FDA Appoints New Officers
FDA has named Virginia Behr as the Center for Drug Evaluation and Research (CDER, www.fda.gov/cder/) ombudsman.
FDA has named Virginia Behr as the Center for Drug Evaluation and Research (CDER, www.fda.gov/cder/) ombudsman. Behr has been with the agency since 1999 and before joining the FDA she worked at the National Institutes of Health (NIH) and Uniformed Services University of the Health Sciences (USUHS) investigating the electrophysiological bases of stimulant drug preference. Behr has been serving as the acting CDER ombudsman for the past four months.
The agency has also selected Edward Cox as director for the Office of Antimicrobial Products (OAP). Cox has been serving as the acting director for OAP since August of 2006. Cox graduated from the University of North Carolina at Chapel Hill and received his medical education at the University of North Carolina School of Medicine.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
